Amgen Reports Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
Go back to Amgen Reports Second Quarter 2017 Financial Results
July 26, 2017 8:34 AM EDT
UBS raised its price target on Amgen (NASDAQ: AMGN) to $180.00 (from $175.00) while maintaining a Neutral rating. 2Q results were better than expectations with a $145M top-line beat. EPS also beat consensus estimates by $0.18.
UBS increased 2017 Enbrel sales estimates to $5.38B from $5B... More
July 26, 2017 6:18 AM EDT
Deutsche Bank raised its price target on Amgen (NASDAQ: AMGN) to $174.00 (from $172.00) while maintaining a Hold rating.
Analyst Andrew Peters called the quarter "solid" but said the near term outlook remains challenged.
"While the results beat expectations, we remain cautious on... More
July 25, 2017 4:04 PM EDT
Amgen (NASDAQ: AMGN) reported Q2 EPS of $3.27, $0.16 better than the analyst estimate of $3.11. Revenue for the quarter came in at $5.81 billion versus the consensus estimate of $5.67 billion.
GUIDANCE:
Amgen sees FY2017 EPS of $12.15-$12.65, versus the consensus of $12.49. Amgen sees... More
